Newsletter WatchNewsletter Watch: Small-cap medical stocksTicker Tape Digest editor Leo Fasciocco recently chose Natus Medical (Nasdaq:BABY) and Kensey Nash (Nasdaq:KNSY) as his favorite small-cap picks. Newsletter Watch: Royce Global ValueGiven the market's high volatility, it may be an ideal time for investors to consider the Royce Global Value Fund (MUTF:RIVFX) — a small-cap fund with a focus on global opportunities within the framework of value-oriented investing. Newsletter Watch: China BAK BatteryRead why Asia Stock Alert editor Tony Sagami recently chose China BAK Battery (Nasdaq:CBAK) as his latest recommendation. Newsletter Watch: Elixir Gambling TechnologiesWith a micro-cap valuation of just $188 million and a “penny stock” price, Elixir Gaming Technologies (AMEX:EGT) is a high-risk company. Newsletter Watch: Beijing betsThis week, we have a pair of intriguing plays on the rise in demand by Chinese consumers for higher quality — and healthier — foods: China Agritech (Nasdaq:CAGC) and American Oriental Bioengineering (Nasdaq:AOB). Newsletter Watch: Favorite small-cap fundsThis week, we follow up on our previous two Newsletter Watch columns, returning to favorite ideas among small-cap funds, as well as take a look at two small caps that fit the "guru strategy" of Warren Buffett. Newsletter Watch: JAKKS PacificOne of Validea editor John Reese's latest picks is children's products retailer JAKKS Pacific (Nasdaq:JAKK), which passes the parameters based on the strategies of Kenneth Fisher, Peter Lynch and Benjamin Graham. Newsletter Watch: Best bets among small cap funds and ETFsThis week, we examine Fidelity Investor editor Jim Lowell's outlook for the small-cap sector, favorite small-cap funds within the Fidelity family and his review of the top five small-cap ETFs. Newsletter Watch: Xinyuan Real EstateHaving just spent several weeks touring China, Global Investing editor Vivian Lewis uncovered several intriguing new ideas, including one small-cap stock in the homebuilding sector — Xinyuan Real Estate (NYSE:XIN). Newsletter Watch: Omrix BiopharmaceuticalsSee why Bill Martin, editor of BullMarket.com and founder of RagingBull.com, recently turned his analysis to Omrix Biopharmaceuticals (Nasdaq:OMRI).
|
|
